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ADP 20
mM
1 38 + 10 84 + 9 0.002
2 53 + 10 94 + 5 0.001
4 72 + 8 98 + 1 0.002
16 85 + 3 98 + 1 0.003
SFFLRN
5 mM
1 2 + 8 62 + 9 <0.001
2 9 + 8 64 + 10 <0.001
4 17 + 8 75 + 6 <0.001
16 15 + 8 58 + 7 0.001
AYPGKF
160
mM
1 7 + 3 39 + 9 0.002
2 9 + 3 44 + 11 0.004
4 13 + 4 53 + 8 <0.001
16 11 + 4 41 + 10 0.01
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Background: Sleep apnea syndrome (SAS) is often observed in patients with acute
coronary syndromes (ACS). It is known that SAS is associated with an increased risk
of cardiovascular events .However, it remains unknown that relationship between high
on-clopidogrel treatment platelet reactivity (HPR) and SAS in patients with ACS
undergoing stent implantation.
Methods: Stent implantation was performed in 62 patients with ACS receiving aspirin
100mg/day and clopidogrel 75mg/day. P2Y12 Reaction Unit (PRU) was determined
on admission, 6 days(acute phase) and 18 days(chronic phase) after stenting with
VerifyNow P2Y12 assay. HPR was deﬁned as PRU S235. Sleep disturbance was
evaluated with Apnomonitor. SAS was deﬁned as apnea-hypopnea index (AHI)S15 .
Patients were divided into 2groups, SAS group (n¼26) and non-SAS group (n¼36).
Results: There were no signiﬁcant differences in baseline characteristics between 2
groups. PRU levels were similar at baseline (27160 vs 27571, p¼0.40). In acute
phase, SAS group had a trend of higher PRU level (27044 vs 24356, p¼0.06).
And in chronic phase, SAS group had higher PRU level (24944 vs 18352,
p¼0.002) and the higher frequency of HPR (70% vs 21%,p¼0.01).
Conclusions: SAS may be related with HPR in both acute and chronic phase of ACS.
These results suggest that assessment of sleep disturbance might be required in pa-
tients with ACS receiving clopidogrel.
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Background: Dual antiplatelet therapy (DAP) with aspirin and a thienopyridine
following coronary stenting is superior to aspirin alone in reducing cardiovascular
events in both the acute coronary syndrome (ACS) and the elective setting. However,
there is no consensus that DAP is more effective and safe to clopidogrel alone in
secondary prevention. We investigate whether clopidogrel alone vs. DAP leads to an
excess of adverse outcomes in acute myocardial infarction (AMI) patients after cor-
onary stenting.
Methods: We studied a consecutive series of 13,348 AMI patients undergoing
successful coronary stenting and evaluated data from patients were discharged on
clopidogrel alone (n¼85, 0.6%) and DAP (n¼13,263, 99.4%) from korea acute
myocardial infarction registry. To eliminate biased estimates, a propensity score
was used and two cohorts of 1:5 nearest neighbor matched patients were
obtained.
Results: Propensity matching identiﬁed two cohorts of 85 patients on clopidogrel
alone and 425 patients on DAP. At a median follow-up period of 11.8 months, there
was no difference in all-cause death (3.1 vs. 3.5%, p¼0.82), cardiovascular death (2.1
vs. 2.4%, p¼0.892) myocardial infarction (MI) (1.6 vs. 1.2%, p¼0.75), revasculari-
zation (6.6 vs. 8.2%, p¼0.583) and cumulative major adverse cardiovascular events
(MACE) (11.3 vs. 12.9%, p¼0.665). Patients with clopidogrel alone compared with
DAP were not associated with increased all-cause death (HR 1.11, 95% CI 0.314-3.93,
p¼0.871), MI (HR 0.38, 95% CI 0.17-11.2, p¼0.763), revascularization (HR 0.808,
95% CI 0.353-1.851, p¼0.615) and MACE (HR 1.129, 95% CI 0.585-2.178,
p¼0.717) during follow up.
Conclusions: In this observation study, clopidogrel alone therapy after coronary
stenting did not increase the mortality and MACE compared with DAP therapy.
However, larger trials are needed to support these observations.
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Background: Early stent thrombosis has been noted with increased frequency in
acute coronary syndrome patients undergoing coronary intervention when treated
with bivalirudin and clopidogrel. We hypothesized that treatment with the more
potent thienopyridine prasugrel would lead to signiﬁcantly greater inhibition of
platelet aggregation (PA) than clopidogrel following termination of bivalirudin
treatment.
Methods: 24 patients referred for intervention with planned bivalirudin therapy, not
previously treated with a P2Y12 inhibitor and not receiving heparins or GP IIb/IIIaJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Phainhibitors were randomized to treatment with either clopidogrel (600 mg) or prasugrel
(60 mg). PA was measured by light transmission aggregometry (LTA) of platelet-rich
plasma in response to P2Y12 and PAR1 and PAR4 thrombin receptor agonists at
baseline and at 1, 2, 4 and 16 h following the cessation of bivalirudin infusion. Platelet
response to agonists: 20 mM ADP, 5 mM SFLLRN, and 160 mM AYPGKF (P2Y12,
PAR1 and PAR4 receptors respectively) was performed. The magnitude of inhibition
of PA for each agonist was calculated as the mean ﬁnal change from baseline in LTA
at each time point.
Results: As compared to clopidogrel, prasugrel led to signiﬁcantly earlier and more
potent inhibition of PA following the discontinuation of bivalirudin. Prasugrel-
mediated inhibition of PA was signiﬁcantly greater than that of clopidogrel at all time
points for ADP as well as PAR1 and PAR4 peptide agonists (Table).Conclusions: Following the cessation of bivalirudin treatment, prasugrel compared
to clopidogrel therapy, causes greater and earlier inhibition of PA in response to
both P2Y12 and thrombin receptor agonists. This is the ﬁrst report of signiﬁcant
inhibition of both thrombin receptors with prasugrel as compared to clopidogrel.
This may explain the prasugrel-mediated reduction in stent thrombosis noted in
clinical trials.
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Background: Surgery is a frequent cause of dual antiplatelet therapy (DAPT)
cessation in patients following percutaneous coronary intervention (PCI). However,
the speciﬁc types of surgery leading to interrupting DAPT have not been described.
Methods: PARIS is a multinational registry of 5018 patients prescribed DAPT
following successful PCI. Pre-speciﬁed categories of DAPT cessation were physician
recommended discontinuation, brief interruption (< 14 days) for a surgical procedure
or disruption (due to bleeding or noncompliance). We examined the patterns and types
of procedures leading to DAPT interruption.
Results: Over 2 years there were 594 DAPT interruptions involving 491 (9.8%)
patients, with 42% occurring within 1 year. Among known recommenders (57.1%),
non-cardiologists (primary care physicians, surgeons, dentists) (51.3%) frequently
recommended interruption. Among cases where the speciﬁc type of surgery was
reported (69.7%), minor procedures comprised the majority (68.4%), compared to
major surgery (31.6%) (ﬁgure). Interruption of only one antiplatelet was more
common (57.2%) [clopidogrel (32.3%), aspirin (24.9%)], with similar patterns seen
for minor and major surgery. Crude rates of cardiac death, MI or ST from
interruption to follow-up were higher after major surgery (7.6% vs 2% P< 0.001)
but did not differ signiﬁcantly when correcting for disruption (4.2% vs 2%
P¼0.08).rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B147
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requiring DAPT interruption, frequently recommended by non-cardiologists and most
commonly due to minor surgery.
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Background: Prasugrel demonstrated superior efﬁcacy in the reductionof events of acute
coronary syndrome (ACS), clopidogrel-naïve, patients treated with percutaneous coro-
nary intervention (PCI), especially in the diabetic (DM) subgroup. The objective of this
study is to assess the efﬁcacy and safety of switching from dual antiplatelet treatment with
clopidogrel to prasugrel inACSDMpatients being treatedwith everolimus-eluting stents.
Methods: Prospective, observational study conducted in 4 different centers. Patients
were included if they met the ADA criteria for established or increased risk for DM.
Platelet reactivity was measured before PCI and 1 month after with 2 different ana-
lyzers (VerifyNow P2Y12 test and Multiplate ADP-HS test); high on-treatment
platelet reactivity (HTPR) was deﬁned as any of the previously demonstrated values:
VerifyNow PRU >208, inhibition of platelet aggregation (IPA) < 20% or Multiplate
AUC>31. The presence of any complication, especially bleeding events, was recor-
ded both before discharge and at 1-month follow-up.
Results: Ninety-six patients were included: 638 years mean age, 77% male, 72%
hypertensive, 66% hyperlipidemic, 32% smokers (plus 23% ex-smokers), 80% ACS
with positive biomarkers, 58% multivessel disease. Only 16% of patients received
insulin. 15% of patients were diagnosed with diabetes and 21% with increased risk for
DM in the index admission. 10% of patients were previously treated with prasugrel
and 5% were changed back to clopidogrel by their treating physicians. Before the PCI,
71 patients (74%) showed HTPR (67% met the VerifyNow criteria, 37% according to
Multiplate results). At 1 month only 14% of patients showed HTPR; 3 of the 4 patients
on clopidogrel treatment (75%) still showed HTPR. After 1 month follow-up only 5
bleeding events were recorded: one caused by coronary perforation after PCI, one
signiﬁcant groin hematoma, 3 minor bleedings (epistaxis, skin hematomas), without
need of subsequent changes in treatment.
Conclusions: Switching from clopidogrel to prasugrel after stent treatment in ACS
diabetic patients is associated with a signiﬁcant reduction in platelet reactivity without
a relevant increase in bleeding complications.
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Background: CYP2C19 gene polymorphisms affect clopidogrel metabolism resulting
in variability in response. We sought to assess the frequency of CYP2C19 variants andB148 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstraassociation of stent thrombosis (ST) in a series of individuals undergoing percuta-
neous coronary intervention (PCI).
Methods: A case-control study of 10 patients with stent thrombosis and 38 patients
were routinely tested for CYP2C19 gene variants using the Verigene (Nanosphere Inc,
Illinois) and iPLEX assays (Sequenom Inc, San Diego). Patients were genotyped for
three single-nucleotide polymorphisms of the CYP2C19 alleles (*2, *3, *17).
Results: Of 48 patients undergoing gene testing 31(65%, 95%CI: 49%, 78%) carried a
loss-of-function (LOF) CYP2C19 allele. Call rate and concordance was 100% be-
tween the two assays. PCI was performed for acute coronary syndrome in 73% of
patients. In patients with a variant allele, 17(55%) were *2, 11 (35%) were *17, and
3(10%) were both *2 and *17. No patient had the CYP2C19*3 variant. LOF alleles
were present in 80% of patients with ST compared to 61% in patients without ST
(OR¼2.6, 95%CI: 0.5,14). Five patients with a LOF allele, had either a clopidogrel
dose increase or were changed to prasugrel, with no in-stent thrombosis in these
patients.
Conclusions: Carriage of a LOF CYP2C19 allele is associated with a higher odds
ratio of in-stent thrombosis in patients on standard dose clopidogrel, highlighting the
need for routine gene testing. Patients with a LOF allele should have alteration of
P2Y12 inhibitor therapy with either a higher dose of clopidogrel or a switch to pra-
sugrel or ticagrelor.
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Background: The aim of this analysis is to evaluate the bleeding risks of new oral
antiplatelet agents in real life.
Methods: All patients with ACS who underwent PCI during admission from September
2011 to December 2013 were included. Baseline characteristics and follow up were
collected prospectively. Bleeding risk was stratiﬁed according to PLATO deﬁnition.
Results: 869 patients were included with a mean age of 62,7 (SD 10,8). Most were
male (81%). Clinical admission: 40% were NSTEMI, 29,3% STEMI and 30,7% un-
stable angina. Median TIMI score was 3 pts, median GRACE score 124 pts and
median CRUSADE 25,7 pts. Clopidogrel was received 54,5%, prasugrel 32,7% and
ticagrelor 12,8%. CRUSADE score was lower in the prasugrel(p< 0,001) and tica-
grelor (p¼0,04)compared with clopidogrel. After a median follow up of 271 days, 92
(11,6%) bleeding events were detected:6,6% minor bleeding,4% mayor bleeding and
1,6% life threatening bleeding. On multivariate analysis STEMI (HR 2,25; CI95%
1,35-3,75;p¼0,002),prasugrel (HR 2,31;CI95% 1,43-1,72; p¼0,001), age (HR
1,036;CI95% 1,010-1,063;p¼0,006) and reduced creatinine clearance (HR 1,74;
CI95% 1,03-2,85;p¼0,037) predicted bleeding events. After analyzing only mayor
and life threatening events, prasugrel was not signiﬁcantly associated with mayor
bleeding events (HR 1,84; CI95% 0,89-3,80; p¼0,097).cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
